The Tobacco Constituent and Biomarker Assessment Core will provide a unique resource for Projects 1-3. Investigators in this Core comprise one of the leading academic laboratories in the world for chemical analysis of tobacco constituents and related metabolites and biomarkers. The following urinary metabolites will be quantified: nicotine equivalents (the total of nicotine, cotinine, and trans-3'-hydroxycotinine and their glucuronides), total NNAL (the total of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides), total NNN (the total of free and glucuronidated N-nitrosonornicotine), mercapturic acids of the volatile carcinogens 1,3-butadiene, benzene, acrolein, crotonaldehyde, and ethylene oxide, and the inflammation and oxidative damage biomarkers 11-?-hydroxy-9,15-dioxo-2,3,4,5-tetranorprostane-1,20-dioic acid (PGE- M) and 9,11,15-trihydroxyprosta-5,13-dien-1-oic acid. We will also quantify the formaldehyde-DNA adduct, /V6-hydroxymethyideoxyadenosine in leukocyte DNA, and minor tobacco alkaloids in urine. These biomarkers will provide crucial information for the research being carried out in Projects 1-3.

Public Health Relevance

Methods for achieving reduction in public health harm from use of tobacco products are critical for decreasing the human cancer toll of tobacco use. The biomarkers being quantified in this core are representative of many of the major carcinogenic and tumor enhancing constituents known to be present in tobacco products. Quantifying these biomarkers will provide an important tool for the evaluation of tobacco products to determine their potential impact on public health.

National Institute of Health (NIH)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Hatsukami, Dorothy K; Donny, Eric C; Koopmeiners, Joseph S et al. (2015) Compensatory smoking from gradual and immediate reduction in cigarette nicotine content. Cancer Epidemiol Biomarkers Prev 24:472-6
Vogel, Rachel Isaksson; Hertsgaard, Louise A; Dermody, Sarah S et al. (2014) Sex differences in response to reduced nicotine content cigarettes. Addict Behav 39:1197-204
Tidey, Jennifer W; Colby, Suzanne M; Xavier, Emily M H (2014) Effects of smoking abstinence on cigarette craving, nicotine withdrawal, and nicotine reinforcement in smokers with and without schizophrenia. Nicotine Tob Res 16:326-34
Smith, Tracy T; Schassburger, Rachel L; Buffalari, Deanne M et al. (2014) Low-dose nicotine self-administration is reduced in adult male rats naïve to high doses of nicotine: implications for nicotine product standards. Exp Clin Psychopharmacol 22:453-9
Dermody, Sarah S; Donny, Eric C (2014) The predicted impact of reducing the nicotine content in cigarettes on alcohol use. Nicotine Tob Res 16:1033-44
Donny, Eric C; Hatsukami, Dorothy K; Benowitz, Neal L et al. (2014) Reduced nicotine product standards for combustible tobacco: building an empirical basis for effective regulation. Prev Med 68:17-22
Hatsukami, Dorothy K; Heishman, Stephen J; Vogel, Rachel Isaksson et al. (2013) Dose-response effects of spectrum research cigarettes. Nicotine Tob Res 15:1113-21
Hatsukami, Dorothy K; Benowitz, Neal L; Donny, Eric et al. (2013) Nicotine reduction: strategic research plan. Nicotine Tob Res 15:1003-13
Hatsukami, Dorothy K; Hertsgaard, Louise A; Vogel, Rachel I et al. (2013) Reduced nicotine content cigarettes and nicotine patch. Cancer Epidemiol Biomarkers Prev 22:1015-24
Tidey, Jennifer W; Rohsenow, Damaris J; Kaplan, Gary B et al. (2013) Separate and combined effects of very low nicotine cigarettes and nicotine replacement in smokers with schizophrenia and controls. Nicotine Tob Res 15:121-9

Showing the most recent 10 out of 11 publications